Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | FOS | P01100 | 1/20 | 0.50 |
| ▸ | JUN | P05412 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 3/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TYR | P14679 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7693884 | 1.00 | MAPT (0.53) | MAPTFOSJUNALDH1A1CYP3A4 | |
| SCHEMBL4055668 | 0.93 | CA12 (0.53) | MAPTALDH1A1RAB9ACA12CA1 | |
| SCHEMBL13845314 | 0.93 | CA12 (0.53) | MAPTALDH1A1RAB9ACA12CA1 | |
| SCHEMBL4055672 | 0.93 | CA12 (0.53) | MAPTALDH1A1RAB9ACA12CA1 | |
| SCHEMBL4065768 | 0.87 | CA12 (0.49) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL4065769 | 0.87 | CA12 (0.49) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL8091741 | 0.86 | CA12 (0.66) | MAPTALDH1A1MAOAMAOBRAB9A | |
| SCHEMBL4283080 | 0.86 | THRB (0.56) | MAPTALDH1A1CYP3A4HPGDRAB9A | |
| SCHEMBL4283078 | 0.86 | THRB (0.56) | MAPTALDH1A1CYP3A4HPGDRAB9A | |
| SCHEMBL1322440 | 0.86 | KMT2A (0.54) | MAPTALDH1A1RAB9ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3116851-B1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INST FOR BIOLOGICAL STUDI (US) | 2023-07-26 | — | — | EP | disclosed |
| US-10301268-B2 | Analogs of fexaramine and methods of making and using | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2019-05-28 | — | — | US | disclosed |
| US-9975856-B2 | Process for the preparation of (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid | GENENTECH, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9656986-B2 | Compositions comprising TPGS-750-M | MYCELL TECHNOLOGIES, LLC (US) | 2017-05-23 | — | — | US | disclosed |
| US-9656985-B2 | Surfactant-enabled transition metal-catalyzed chemistry | MYCELL TECHNOLOGIES, LLC (US) | 2017-05-23 | — | — | US | disclosed |
| US-20170101380-A1 | PROCESS FOR THE PREPARATION OF (E)-3-(4-((E)-2-(2-CHLORO-4-FLUOROPHENYL)-1-(1H-INDAZOL-5-YL)BUT-1-EN-1-YL)PHENYL)ACRYLIC ACID | GENENTECH, INC. (US) | 2017-04-13 | — | — | US | disclosed |
| WO-2017060326-A1 | PROCESS FOR THE PREPARATION OF (E)-3-(4-((E)-2-(2-CHLORO-4-FLUOROPHENYL)-1-(1H-INDAZOL-5-YL)BUT-1-EN-1-YL)PHENYL)ACRYLIC ACID | F. HOFFMANN-LA ROCHE AG (CH) | 2017-04-13 | — | — | WO | disclosed |
| US-20170073322-A1 | Surfactant-Enabled Transition Metal-Catalyzed Chemistry | MYCELL TECHNOLOGIES, LLC (US) | 2017-03-16 | — | — | US | disclosed |
| US-20170066724-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-03-09 | — | — | US | disclosed |
| US-20160347677-A1 | Surfactant-Enabled Transition Metal-Catalyzed Chemistry | MYCELL TECH LLC (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160340332-A1 | Compositions Comprising TPGS-750-M | MYCELL TECH LLC (US) | 2016-11-24 | — | — | US | disclosed |
| US-8853390-B2 | Processes for preparing 1,2-substituted cyclopropyl derivatives | ABBVIE INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8785665-B2 | Surfactant-enabled transition metal-catalyzed chemistry | MYCELL TECHNOLOGIES, LLC (US) | 2014-07-22 | — | — | US | disclosed |
| EP-2398780-B1 | CYCLOPROPYL AMIDE DERIVATIVES TARGETING THE HISTAMINE H3 RECEPTOR | ASTRAZENECA AB (SE) | 2013-04-17 | — | — | EP | disclosed |
| US-20130053566-A1 | CATIONIC PALLADIUM COMPLEXES COMPRISING DIAMINO CARBENE LIGANDS AND THEIR USE IN CATALYSIS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2013-02-28 | — | — | US | disclosed |
| US-20120071651-A1 | Processes for Preparing 1,2-Substituted Cyclopropyl Derivatives | ABBOTT LABORATORIES (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110130562-A1 | Surfactant-Enabled Transition Metal-Catalyzed Chemistry | MyCell Holdings Limited | 2011-06-02 | — | — | US | disclosed |
| US-6342627-B1 | ESTER INTERCHANGE WITH ALCOHOL IN THE PRESENCE OF LANTHANOIDE METAL ALKOXIDE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053566-A1 | CATIONIC PALLADIUM COMPLEXES COMPRISING DIAMINO CARBENE LIGANDS AND THEIR USE IN CATALYSIS | MLX, LBR, LRRK2 | MAPT 4116/4885FOS 4374/4885JUN 1030/4885 |
| US-20170066724-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | FXR2, FXR1, SLC10A2 | MAPT 4643/4885FOS 1297/4885JUN 2635/4885 |
| US-20160340332-A1 | Compositions Comprising TPGS-750-M | S100A10, S100A6, TPR | MAPT 1142/4885FOS 2150/4885JUN 813/4885 |
| US-20170073322-A1 | Surfactant-Enabled Transition Metal-Catalyzed Chemistry | SOD1, SMURF1, MUC1 | MAPT 1553/4885FOS 3475/4885JUN 888/4885 |
| US-10301268-B2 | Analogs of fexaramine and methods of making and using | FXR2, FXR1, SLC10A2 | MAPT 4643/4885FOS 1297/4885JUN 2635/4885 |
| US-20110130562-A1 | Surfactant-Enabled Transition Metal-Catalyzed Chemistry | SOD1, SMURF1, MUC1 | MAPT 1553/4885FOS 3475/4885JUN 888/4885 |
| US-20170101380-A1 | PROCESS FOR THE PREPARATION OF (E)-3-(4-((E)-2-(2-CHLORO-4-FLUOROPHENYL)-1-(1H-INDAZOL-5-YL)BUT-1-EN-1-YL)PHENYL)ACRYLIC ACID | ESR1, ESR2, GPER1 | MAPT 4135/4885FOS 1784/4885JUN 1202/4885 |
| US-20120071651-A1 | Processes for Preparing 1,2-Substituted Cyclopropyl Derivatives | HRH3, HRH4, HRH1 | MAPT 2094/4885FOS 4590/4885JUN 4030/4885 |
| US-20160347677-A1 | Surfactant-Enabled Transition Metal-Catalyzed Chemistry | SOD1, SMURF1, MUC1 | MAPT 1553/4885FOS 3475/4885JUN 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.